This review summarises current understanding of how bone is sculpted through adaptive
processes, designed to meet the mechanical challenges it faces in everyday life and athletic …

Background Osteoporosis affects mostly postmenopausal women, leading to deterioration of
the microarchitectural bone structure and low bone mass, with an increased fracture risk with …

Background Long-term safety and efficacy of osteoporosis treatment are important because
of the chronic nature of the disease. We aimed to assess the long-term safety and efficacy of …

Introduction The application of high-resolution peripheral quantitative computed tomography
(HR-pQCT) to assess bone microarchitecture has grown rapidly since its introduction in …

Objective: This report summarizes data on traditional and nontraditional manifestations of
primary hyperparathyroidism (PHPT) that have been published since the last International …

To treat systemic bone loss as in osteoporosis and/or focal osteolysis as in rheumatoid
arthritis or periodontal disease, most approaches target the osteoclasts, the cells that resorb …

The FREEDOM study and its Extension provide long-term information about the effects of
denosumab for the treatment of postmenopausal osteoporosis. Treatment for up to 8 years …

Dual-energy X-ray absorptiometry (DXA) was the first imaging tool widely utilized by
clinicians to assess fracture risk, especially in postmenopausal women. The development of …

Aims: To describe the mechanisms of action of denosumab, a novel antiresorptive agent,
contrasting it with other antiresorptive and anabolic osteoporosis treatments. Methods …

Abstract Denosumab (Prolia®; Pralia®) is a human monoclonal antibody targeting the key
bone resorption mediator RANKL. The drug is administered via subcutaneous injection once …